Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:9:177-90.
doi: 10.2147/TCRM.S30947. Epub 2013 Apr 26.

An update of teriflunomide for treatment of multiple sclerosis

Jiwon Oh  1 , Paul W O'Connor
Affiliations

An update of teriflunomide for treatment of multiple sclerosis

Jiwon Oh et al. Ther Clin Risk Manag. 2013.

Abstract

There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. This review will summarize teriflunomide's historical development, clinical pharmacology, studies in animals, clinical trials, and safety data, and will end with a discussion of the role of teriflunomide in MS in the context of existing treatment options.

Keywords: clinical trials; multiple sclerosis; review; teriflunomide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Related chemical structures of leflunomide and teriflunomide.
Figure 2
Figure 2
Mechanism of action of teriflunomide. Note: Reprinted from Tallantyre, et al. Int MS J. 2008;15:62–68 with permission from Cambridge Medical Publications (CMP). Abbreviation: DHODH, dihydroorotate dehydrogenase.
Figure 3
Figure 3
Teriflunomide safety-monitoring guidelines. Abbreviations: CBC, complete blood count; LFTs, liver-function tests (aspartate transaminase, alanine transaminase, alkaline phosphatase, bilirubin).
See this image and copyright information in PMC

References

    1. Marriott JJ, O’Connor PW. Emerging therapies in relapsing-remitting multiple sclerosis. Rev Recent Clin Trials. 2010;5:179–188. - PubMed
    1. Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2003;1:CD002047. - PMC - PubMed
    1. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity – I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol. 1985;7:7–18. - PubMed
    1. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76:950–960. - PubMed
    1. Posevitz V. Teriflunomide selectively suppresses antigen induced T cell expansion in a TCR avidity dependent fashion. Paper presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10–13, 2012; Lyon, France.

LinkOut - more resources